ImmunoCellular Therapeutics, Ltd.

Period: May 1, 2012 to Dec 11, 2015

Lead Plaintiff Deadline: Jun 30, 2017

Summary of Case:

A securities class action has been filed against ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular) on bbehalf of those who purchased or otherwise acquired ImmunoCellular common stockbetween May 1, 2012 through December 11, 2013.  This case has been filed in the USDC - California (Central).

The Complaint alleges that prior to and throughout the Class Period, defendants orchestrated a scheme to manipulate and artificially inflate the stock price of ImmunoCellular. Unbeknownst to the market and ImmunoCellular investors, beginning in September 2011, ImmunoCellular hired Lidingo to pump up the value of ImmunoCellular stock. This endeavor included a campaign of planting phony analyst reports and news articles that fawned over the Company. In many cases, these phony media reports were written under aliases, and the authors failed to reveal that they were paid by Lidingo. The authors also failed to reveal that ImmunoCellular had complete editorial control over their work. By virtue of this scheme, the market was conditioned to believe that the Company's clinical studies for its lead product candidate, ICT-107, were progressing as the placement of these fraudulent media reports were often timed to coincide with the Company announcements of ICT-107, so to have maximum impact upon ImmunoCellular's share price. As a result of this scheme, ImmunoCellular's stock price rocketed to a Class Period high of $3.88 per share on June 1, 2012, from a price as low as $1.53 per share prior to the initiation of the scheme.

On December 11, 2013, after the market closed, the Company revealed that the intent-to-treat population, which was the primary endpoint for its ICT-107 Phase II study, "did not reach statistical significance" because it failed to increase overall survival in patients diagnosed with glioblastoma multiforme. As a result of the disclosure on December 11, 2013, ImmunoCellular stock declined $1.62 per share or nearly 60%, to close at $1.10 per share on December 12, 2013. It is alleged that as a result of defendants' wrongful acts and misleading statements and omissions, and the precipitous decline in the market value of the Company's common stock, Plaintiff and other Class members have suffered significant losses and damages.

If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.

Join This Action